Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inhibitor Therapeutics ( (INTI) ) just unveiled an update.
On March 31, 2026, Inhibitor Therapeutics announced progress in its pharmacokinetic clinical program for a proprietary itraconazole formulation targeting surgically eligible basal cell carcinomas in Gorlin Syndrome, with a three-way crossover study in healthy adults in Malaysia advancing through dosing periods scheduled in April and bioanalysis expected to begin in early May. The company also highlighted its amorphous formulation strategy to improve itraconazole solubility and absorption and disclosed plans for a new global patent application on the composition, a move that could strengthen its intellectual property position, support an eventual U.S. NDA filing under the 505(b)(2) pathway, and enhance the strategic value of the BCCNS program for future commercialization and partnering.
In parallel with the clinical study designed to generate what it expects will be the final pharmacokinetic data needed before seeking FDA approval, Inhibitor emphasized that the planned patent, if granted, would be wholly owned without royalty obligations and would complement its existing oncology-focused IP portfolio. For patients with Gorlin Syndrome, who often endure repeated surgeries and related morbidity, the itraconazole program is positioned as a differentiated, non-surgical therapeutic approach that could address a significant unmet medical need while potentially improving the company’s standing in the niche oncology and rare disease markets.
More about Inhibitor Therapeutics
Inhibitor Therapeutics, Inc. is a publicly traded, clinical-stage pharmaceutical development company focused on developing and commercializing innovative therapies based on repurposed, already approved active pharmaceutical ingredients with patent protection. Its lead program is itraconazole, being advanced as a treatment for surgically eligible basal cell carcinomas in patients with Basal Cell Carcinoma Nevus Syndrome, also known as Gorlin Syndrome, a rare hereditary disorder marked by recurrent skin cancers.
Average Trading Volume: 39,803
Technical Sentiment Signal: Buy
Current Market Cap: $18.77M
Find detailed analytics on INTI stock on TipRanks’ Stock Analysis page.